

Watchman In Asia Pacific (WASP) Registry 2 Year Outcomes

T. Santoso Medistra Hospital, Jakarta, Indonesia

Epidemiological Studies Have Demonstrated Significant Differences In *Ischemic Stroke Risk & Risk Of Bleeding* In *Asian Populations With NVAF* vs. Other Ethnicities¹⁻³

Increased stroke risk commencing from a *younger age* (from age 50 years) in Asians compared to non-Asians^{1,3.} This creates potential *increased duration of exposure to (N)OAC* & *long term compliance*

Rates of *under-treatment* with OAC remain stubbornly high in Asian countries despite the global penetration of NOAC into clinical practice⁴

Compared to non-Asians, Asians are at significantly *higher risk of warfarin-related intracranial bleeding* (HR = 4.06)²

Possible link between *macro- and micro-angiopathy* which are more prevalent in Asian populations (may be associated with an *increased risk of intracranial bleeding)*⁵

1. Chan TF, et al. Stroke 2016l; 47:2462-2469; 2.Shen AY, et al.J Am Coll Cardiol 2007; 50:309-315; 3. Bai Y, et al. Chest 2017; 152:810-820; 4. Huisman MV, et al. J Am Coll Cardiol 2017; 69:777-785; 5.Bang OY, et al. J Stroke 2016; 18:169-178

AF Poses A Considerable Threat To Health Care In Asia:


Under-treatment & High Stroke Rate Despite Treatment

AF in China The stroke rate in Chinese AF patients ranged from 6% to13% 3,4 Large-cohort study also reported a *increasing trend in the incidence* of AF and AF-related stroke over the past decade³ Despite the high stroke incidence, only 4.1% of Chinese pts with AF are currently under warfarin therapy¹⁻³ AF patients taking warfarin did not have lower stroke rate compared to patients taking Aspirin, probably due to a poor INR control 5



1. Lip GY, et al. Chest 2012;142:1489-1498; 2.Rahman F, et al. Nature reviews. Cardiology. 2014;11:639-654 ; 3. Guo Y, et al. Chest. 2015;147:109-119; 4. Zhou Z, et al. J Epidemiol. 2008;18:209-216; 5. Guo Y, et al. Chest. 2015;148:62-72

Annual Risk of Stroke & Systemic Embolization for Asians & Non-Asians in 3 Clinical Trials of NOAC



Big issue: higher risk of stroke & systemic embolization in Asian patients on (N)OAC

Connolly SJ, et al. N Engl J Med 2009; 361: 1139-1151; Hori M, et al. Stroke 2013; 44: 1891-1896; Patel MR, et al. N Engl J Med 2011; 365: 883-891; Granger CB, et al. N Engl J Med 2011; 365: 981-992; Goto S, et al. Eur Heart J 2013; 34 (Abstr. Suppl): 1039.

WATCHMAN[™] Asia Pacific Study (WASP)


Asia Pacific Prospective Multicentre Non-randomized Cohort Study* 201 pts enrolled between January 2014 and October 2015 across 7 countries



nicalTrials.gov (NCT01972295)

Phillips K, Santoso T, et al. WASP study. IJC Heart & Vasculature 2019;23:1-9

WATCHMANTM Asia Pacific Study (WASP) Asia Pacific Prospective Multicentre Non-randomized Cohort Study* 201 pts enrolled between January 2014 and October 2015 across 7 countries Breakdown of <u>study cohort</u> by enrolling country with Asian patients in blue and Non-Asian patients in red



patient in Australia was Asian, and has been included in the appropriate subgroup in the analyses

Note: *One Australian patient was Asian.

Phillips K, Santoso T, et al. WASP study. IJC Heart & Vasculature 2019;23:1-9

WATCHMAN[™] Asia Pacific Study (WASP)

	Asian N=107	Non Asian N=94	P value
Age	70.7 <u>+</u> 9.4	70.8 <u>+</u> 9.4	0.95
Age >80 yrs old	14.0%	17.0%	0.56
Male	62.6%	72.3%	0.18
CHADS ₂ Score	2.5 <u>+</u> 1.3	2.4 <u>+</u> 1.4	0.49
CHA ₂ DS ₂ - score	4.1 <u>+</u> 1.7	3.7 <u>+</u> 1.6	0.08
CHA ₂ DS ₂ - score (%)			0.25
<u>≤</u> 1 (%)	8.4	7.4	
2-3 (%)	29.9	41.5	
<u>≥</u> 4 (%)	61.7	51.1	
HAS-BLED score	2.2 <u>+</u> 1.3	2.1 <u>+</u> 0.9	0.66
HAS-BLED score (%)			0.28
< 3 (%)	65.4	73.4	
> 3 (%)	34.6	26.6	
Paroxysmal AF pattern	54.2%	47.3%	0.40

TC

Phillips K, Santoso T, et al. WASP study. IJC Heart & Vasculature 2019;23:1-9

WATCHMAN[™] Asia Pacific Study (WASP)

	Asian N=107	Non Asian N=94	P value
CHF (%)	20.6	10.6	0.08
Hypertension (%)	84.1	83.0	0.85
Age <u>></u> 75 (%)	38.3	34.0	0.56
Age 65-74 (%)	43.0	44.7	0.89
Diabetes (%)	46.7	19.1	< 0.0001
History of TIA/stroke (%)	30.8	45.7	0.04
Vascular disease	39.3	23.4	0.02
Abnormal renal function (%)	14.0	7.4	0.18
Abnormal liver function (%)	2.8	1.1	0.62
Hx ischemic /hemorrhagic stroke (%)	28.0	35.1	0.29
Prior major / predisposition to bleeding (%)	19.6	18.1	0.86
Labile INR (%)	20.6	4.3	0.0006
Concomitant use of drug (%)	33.6	50.0	0.02
Alcohol abuse (%)	2.8	13.8	0.007
LV dysfunction (LVEF \leq 40%)(%)	7.5	5.4	0.58

TC

WATCHMAN[™] Asia Pacific Study (WASP): Procedural Results

	Asian N=107	Non Asian N=94	P value
Successful implant	99.1%	97.9%	0.60
LAA seal			
- Complete seal or jet < 5 mm	100%	100%	NS
LAA diameter			
- Mean <u>+</u> SD	23.4 <u>+</u> 4.1	21.2 <u>+</u> 1.3.2	<0.0001
- Median	23.00	21.50	
Last device size used (mm)			
- Mean <u>+</u> SD	27.4 <u>+</u> 3.4	25.3 <u>+</u> 3.2	<0.0001
- Median	27	24	
Compression of last device size used			
- Mean <u>+</u> SD	17 7%	17 6%	0.93
- Median	16%	17%	

WATCHMAN[™] Asia Pacific Study (WASP) Implant Procedure Safety

Device/procedure related post implant SAEs	Asian No of events	Non Asian No of events
Pericardial effusion requiring intervention	2	0
Hypotension	0	1
Vascular access major bleeding	0	1
Pulmonary edema	0	1
Oesophageal tear due to implant TEE causing death day 32	1	0
Femoral AV fistula	1	0
Device embolization	0	0
Stroke	0	0


Device/procedure related post implant SAEs	Asians	Non Asian	All pts KM event
	KM event rate	KM event rate	rate
Kaplan-Meier event rate 7 days	2.9%	3.2%	3.0%
	(0.8, 7.5%)	(0.9, 8.3%)	(1.2, 6.1%)
Kaplan-Meier event rate 30 days	3.8%	3.2%	3.5%
	(1.3, 8.8%)	(0.9, 8.3%)	(1.6, 6.8%)

WATCHMAN[™] Asia Pacific Study (WASP): Imaging On Follow Up

	Asian N=107	Non Asian N=94
Follow up imaging	84.9%	88%
- TEE	90.7%	100%
- CT scan	9.3%	0%
Device embolization	0%	0%
Successful LAA closure with residual leak < 5 mm	100%	100%
Device associated thrombus	2	3
- Neurological sequelae	0	0



WASP: Medications Post Implant & At First Medication Discontinuation During Follow-up Visit



Asian Non-Asian

Asian Non-Asian

Medications used by subjects (A) post-implant, & (B) at first medication discontinuation follow-up visit.


Single APT = single-antiplatelet therapy, DAPT = dual-antiplatelet therapy, NOAC = novel oral anticoagulant

WASP: Event Rates Per Patient Years

	Asia	an	Non-	Asian	
	n=1	07	n=	94	
					P-value
	Rate Per		Rate Per		(Asian vs
Event	100 Pt-Yrs	95% CI	100 Pt-Yrs	95% CI	Non-Asian)
Death	5.04	(2.71-9.36)	1.16	(0.29-4.63)	0.06
Ischaemic Stroke SAE	1.02	(0.25-4.06)	2.39	(0.90-6.36)	0.32
Ischaemic Stroke/TIA/SE SAE	1.02	(0.25-4.06)	3.02	(1.26-7.25)	0.19
Major Bleeding SAE	1.03	(0.26-4.11)	3.68	(1.65-8.20)	0.12
Non-Procedure or Device- Related Major Bleeding SAE	0.51	(0.07-3.65)	3.03	(1.26-7.28)	0.11

Ischemic Stroke In WASP

Expected vs Observed Event Rates per 100 Patient Years




Effectiveness in stroke reduction vs. estimated in the absence of therapy for comparable CHA₂DS₂-VASc scores based on Friberg et al. EHJ 2012

77% relative risk reduction for the overall population, 89% reduction for Asian patients & 62% reduction for non-Asians

TCTAP 2019

Bleeding Events In WASP Expected vs Observed Event Rates per 100 Patient Years



49% <u>relative risk reduction</u> for bleeding events but a more pronounced relative risk reduction in Asian subjects as compared with non-Asians (77% versus 14%)

WASP: Serious Major Bleeding Events

	Days (Post-Implant)	Medication at time of event
Asian (n=107)		
Pericardial tamponade	0	aspirin
Gastrointestinal	74	DAPT
Non-Asian (n=94)		
Vascular Access	0	DAPT
Gastrointestinal†	1	NOAC
Gastrointestinal†	38	NOAC
Gastrointestinal	23	Warfarin
Gastrointestinal	72	NOAC
Varicose vein≠	102	aspirin
Gastrointestinal	555	aspirin
Gastrointestinal≠	561	aspirin

+, *≠* same patient experienced 2 major bleeding events

Guidelines & Recommendations On LAA Closure With The Watchman Device[™]

Guideline	Recommendation to consider LAAC	Class	Level of evidence	
ESC AF Guideline 2016 ¹	Pts with high stroke risk & contraindication for long term OAC	llb	В	
EHRA/EAPCI 2014 ² LAAC Expert Consensus	Pts with high bleeding risk (HASBLED > 3), contraindications for (D)OACs or based on informed pts preference	NA	NA	
ESC/EACTS Guidelines on Myocardial Revascularization 2014 ³	Pts with high stroke risk who are contraindicated for long term antiplatelet & OAC therapy	llb	в	
AHA/ASA 2014 Stroke Guidelines ⁴	Pts with high stroke risk who are unsuitable for anticoagulation	llb	В	
FDA label (March 2015)	Non-valvular AF pts eligible for OAC who have an appropriate reason to seek a non-pharmacological alternative to warfarin			
(D)OACs: (direct) oral anticoagulants; OAC: oral anticoagulation; NA: not applicable				

1. Kirchhof P, et al. European Heart Journal (2016) 37, 2893–2962; 2. Meier B, et al. EuroIntervention 2014;10: 1109-1125; 3. Windecker S, et al. Eur Heart J 2014;35:2541-2619; 4. Meschia JF, et al. Stroke 2014:45:3754-3852; 5. Maisel WH. Available at: http://www.accessdata.fda.gov/cdrh docs/pdf13/P130013a.pdf.

Summary

- Epidemiological studies have demonstrated significant differences in ischemic stroke risk & risk of bleeding (including hemorrhagic stroke) in Asian populations with non-valvular AF compared with other ethnicity
 - 2. *Real world experience with Watchman LAAC in Asia-Pacific* region has shown high successful implant rate, low peri-procedural risk, & efficacious stroke prevention with low bleeding risk on *long term follow up*
 - 3. Another notable finding was a *larger mean LAA ostial diameter & median device size used in Asian patients* compared to non-Asians. This is important as LAA size was recognized as *an independent risk factor for stroke* in the SPAF study
 - 4. Current Clinical Guidelines support the use of LAA device closure for patients with high stroke risk & contraindications to long therm (N)OAC. The *current WASP study provides additional evidence that the Guidelines are also directly applicable to patients of Asian ethnicity*
 - 5. As *LAA closure* provides life-long stroke prophylaxis without the need for daily OAC, it is even *more attractive to use in Asian patients*.